Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. Fundamental Analysis
Cosmo Pharmaceuticals N.V. (CMOPF) shows weak financial fundamentals with a PE ratio of -425.10, profit margin of -3.46%, and ROE of -0.77%. The company generates $0.1B in annual revenue with weak year-over-year growth of 1.88%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 45.0/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CMOPF's fundamental strength across five key dimensions:
Efficiency Score
WeakCMOPF struggles to generate sufficient returns from assets.
Valuation Score
ModerateCMOPF shows balanced valuation metrics.
Growth Score
ModerateCMOPF shows steady but slowing expansion.
Financial Health Score
ExcellentCMOPF maintains a strong and stable balance sheet.
Profitability Score
WeakCMOPF struggles to sustain strong margins.
Key Financial Metrics
Is CMOPF Expensive or Cheap?
P/E Ratio
CMOPF trades at -425.10 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CMOPF's PEG of 4.54 indicates potential overvaluation.
Price to Book
The market values Cosmo Pharmaceuticals N.V. at 3.19 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 228.19 times EBITDA. This signals the market has high growth expectations.
How Well Does CMOPF Make Money?
Net Profit Margin
For every $100 in sales, Cosmo Pharmaceuticals N.V. keeps $-3.46 as profit after all expenses.
Operating Margin
Core operations generate -5.49 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.77 in profit for every $100 of shareholder equity.
ROA
Cosmo Pharmaceuticals N.V. generates $-0.59 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cosmo Pharmaceuticals N.V. generates limited operating cash flow of $-11.96M, signaling weaker underlying cash strength.
Free Cash Flow
Cosmo Pharmaceuticals N.V. generates weak or negative free cash flow of $-16.20M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.00 in free cash annually.
FCF Yield
CMOPF converts -1.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-425.10
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.54
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.19
vs 25 benchmark
P/S Ratio
Price to sales ratio
14.93
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.18
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.01
vs 25 benchmark
ROA
Return on assets percentage
-0.01
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How CMOPF Stacks Against Its Sector Peers
| Metric | CMOPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -425.10 | 28.25 | Better (Cheaper) |
| ROE | -0.77% | 780.00% | Weak |
| Net Margin | -3.46% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.01 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 7.18 | 4.66 | Strong Liquidity |
| ROA | -0.59% | -14687.00% (disorted) | Weak |
CMOPF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cosmo Pharmaceuticals N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
281.76%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
586.44%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
870.62%
Industry Style: Defensive, Growth, Innovation
High Growth